Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Part of paid clinical trials in Tampa, Florida.

Sponsor
Arkadiusz Z. Dudek, MD
Study ID
NCT03502746
Phase
PHASE2
Status
Terminated

Conditions

  • Mesothelioma, Malignant

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab 240mg, IV over 30 minutes.
  • Ramucirumab — DRUG
    8mg/kg, IV over 60 minutes.

Study Details

This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.

Key Dates

Start date
Jun 26, 2018
Status verified
Apr 2024
Primary completion
May 11, 2022
Completion
Nov 9, 2023

Study Design

Enrollment
34 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab + Ramucirumab
    Nivolumab 240mg IV + Ramucirumab 8mg/kg IV

Primary Outcome Measure

Response Rate [ Time Frame: Up to a maximum of 23 months ]

Locations (4)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612-
University of MarylandBaltimoreMaryland21201-
Karmanos Cancer Center (Wayne State University)DetroitMichigan48201-
HealthPartners Institute Regions Cancer Care CenterMinneapolisMinnesota55440-

Find similar trials in Tampa, FL

By research site
Moffitt Cancer Center· Tampa, FLUniversity of Maryland· Baltimore, MDKarmanos Cancer Center (Wayne State University)· Detroit, MIHealthPartners Institute Regions Cancer Care Center· Minneapolis, MN

Related Studies